S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Better Than Oil Stocks (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
Obama’s 2024 Confession (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Better Than Oil Stocks (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
Obama’s 2024 Confession (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Better Than Oil Stocks (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
Obama’s 2024 Confession (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Stock ideas from the 2024 Microcap Conference
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
How major US stock indexes fared Friday, 2/23/2024
Better Than Oil Stocks (Ad)
In his annual letter, Warren Buffett tells investors to ignore Wall Street pundits
MarketBeat Week in Review – 2/19 - 2/23
Obama’s 2024 Confession (Ad)
Closing prices for crude oil, gold and other commodities
Mark Zuckerberg Is Sitting on a Huge Stockpile of AI Chips as Companies Compete for Limited Supplies
NASDAQ:RLYB

Rallybio (RLYB) Stock Price, News & Analysis

$1.70
-0.13 (-7.10%)
(As of 02/23/2024 ET)
Today's Range
$1.68
$1.87
50-Day Range
$1.25
$2.91
52-Week Range
$1.23
$9.88
Volume
182,501 shs
Average Volume
310,193 shs
Market Capitalization
$64.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.20

Rallybio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
676.5% Upside
$13.20 Price Target
Short Interest
Healthy
4.35% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.80) to ($1.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.33 out of 5 stars

Medical Sector

343rd out of 939 stocks

Pharmaceutical Preparations Industry

156th out of 439 stocks


RLYB stock logo

About Rallybio Stock (NASDAQ:RLYB)

Rallybio Corporation, a clinical-stage biotechnology company, engages in identifying, accelerating, and development of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

RLYB Stock Price History

RLYB Stock News Headlines

Billionaires Are Now FLOODING Into Gold
Ray Dalio, John Paulson, and many others all recommend you own gold right now. But did you know there's another huge investor (worth more than all the world's billionaires COMBINED) buying gold by the ton? That's why the best move to make right now could be this little-known gold investment (which you can get started with for just $5).
[BREAKING] Pentagon to Spend Billions on "Living Missile"
Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!
Rallybio Corp RLYB
Expert Ratings for Rallybio
Rallybio GAAP EPS of -$0.45
Rallybio: Q3 Earnings Insights
See More Headlines
Receive RLYB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/06/2023
Today
2/24/2024
Next Earnings (Estimated)
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RLYB
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.20
High Stock Price Target
$18.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+676.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-66,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.29 per share

Miscellaneous

Free Float
35,602,000
Market Cap
$64.24 million
Optionable
Not Optionable
Beta
-2.05
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. Martin W. MacKay Ph.D. (Age 68)
    Co-Founder & Executive Chairman
    Comp: $707.07k
  • Dr. Stephen Uden M.B (Age 66)
    M.D., Co-Founder, President, CEO & Director
    Comp: $707.07k
  • Mr. Jonathan I. Lieber M.B.A. (Age 54)
    CFO & Treasurer
  • Ms. Ami Bavishi
    Head of Investor Relations & Corporate Communications
  • Dr. Steven W. Ryder F.A.C.P (Age 72)
    M.D., Chief Medical Officer














RLYB Stock Analysis - Frequently Asked Questions

Should I buy or sell Rallybio stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rallybio in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RLYB shares.
View RLYB analyst ratings
or view top-rated stocks.

What is Rallybio's stock price target for 2024?

6 equities research analysts have issued 1-year target prices for Rallybio's shares. Their RLYB share price targets range from $8.00 to $18.00. On average, they expect the company's share price to reach $13.20 in the next twelve months. This suggests a possible upside of 676.5% from the stock's current price.
View analysts price targets for RLYB
or view top-rated stocks among Wall Street analysts.

How have RLYB shares performed in 2024?

Rallybio's stock was trading at $2.39 at the start of the year. Since then, RLYB stock has decreased by 28.9% and is now trading at $1.70.
View the best growth stocks for 2024 here
.

When is Rallybio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our RLYB earnings forecast
.

How were Rallybio's earnings last quarter?

Rallybio Co. (NASDAQ:RLYB) posted its earnings results on Monday, March, 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $0.14.

When did Rallybio IPO?

(RLYB) raised $80 million in an initial public offering (IPO) on Thursday, July 29th 2021. The company issued 5,750,000 shares at $13.00-$15.00 per share.

Who are Rallybio's major shareholders?

Rallybio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Novo Holdings A S (4.68%), abrdn plc (4.57%), Vanguard Group Inc. (2.82%), Blue Owl Capital Holdings LP (0.93%), Citadel Advisors LLC (0.84%) and Northern Trust Corp (0.66%). Insiders that own company stock include Jeffrey M Fryer, Jonathan I Lieber, Kush Parmar, Martin Mackay, Opportunities I LP 5Am and Stephen Uden.
View institutional ownership trends
.

How do I buy shares of Rallybio?

Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RLYB) was last updated on 2/24/2024 by MarketBeat.com Staff